Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

-0.65 (-3.46%)
Earnings Announcements

Kiniksa Reports Positive Data From Trial Of Mavrilimumab In Giant Cell Arteritis

Published: 10/06/2020 12:31 GMT
Kiniksa Pharmaceuticals Ltd (KNSA) - Kiniksa Announces Positive Data From Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis.
Kiniksa Pharmaceuticals Ltd - Mavrilimumab Was Well-tolerated in Trial.
Kiniksa Pharmaceuticals Ltd - There Were No Drug-related Serious Adverse Events in Trial.
Kiniksa Pharmaceuticals - Both Primary and Secondary Efficacy Endpoints in Phase 2 Trial of Mavrilimumab Achieved Statistical Significance.
Kiniksa Pharmaceuticals Ltd - Data Expected From Randomized, Double-blind, Placebo-controlled Investigator-initiated Study in U.S. in Q4 of 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.61

More details on our Analysts Page.